JNTU Pharm. D V Year CLINICAL PHARMACOKINETICS AND PHARMACOTHERAPEUTIC DRUG MONITORING Previous Question Paper (April-2023 - R08)

Dosing in pediatric and obese populations requires specialized adjustments due to significant physiological and pharmacokinetic differences compared to healthy adults. These adjustments are critical to ensure therapeutic efficacy while minimizing toxicity.

Pediatric Dosing: Pediatric patients are not miniature adults; their pharmacokinetic parameters (absorption, distribution, metabolism, and excretion) change dynamically with age, organ maturation, and body composition. Dosing is typically calculated using weight-based or surface area-based methods.

1. Weight-based dosing: The most common method, expressing dose as mg/kg. It is generally reliable for children older than one year but may underestimate requirements in neonates due to higher total body water and lower fat content.
2. Body Surface Area (BSA) based dosing: Calculated using formulas like the Mosteller formula (BSA = sqrt((height(cm) × weight(kg)) / 3600)). BSA correlates better with physiological functions like cardiac output and renal clearance than weight alone, making it preferred for drugs with a narrow therapeutic index, such as chemotherapeutic agents.
3. Age-based rules: Older empirical rules like Young’s rule or Fried’s rule are largely obsolete in modern clinical practice due to their lack of precision regarding physiological maturation.

Obese Patient Dosing: Obesity alters the volume of distribution (Vd) and clearance (CL) of drugs, necessitating adjustments based on the drug's physicochemical properties.

1. Lipophilic drugs: Drugs like diazepam or fentanyl have a larger Vd in obese patients due to increased adipose tissue. Loading doses are often increased based on Total Body Weight (TBW) to achieve therapeutic concentrations.
2. Hydrophilic drugs: Drugs like aminoglycosides or digoxin distribute primarily into lean body mass. Dosing should be based on Ideal Body Weight (IBW) or Adjusted Body Weight (ABW) to avoid toxicity.
3. Adjusted Body Weight (ABW): Calculated as ABW = IBW + 0.4(TBW - IBW). This is frequently used for drugs where both lean mass and adipose tissue contribute to distribution.
4. Renal and Hepatic Clearance: Obesity can increase glomerular filtration rate (GFR) and hepatic blood flow, potentially increasing the clearance of certain drugs. Clinicians must monitor serum concentrations (TDM) to adjust maintenance doses, as standard weight-based calculations may lead to sub-therapeutic levels.

In both populations, clinical judgment, monitoring of physiological markers (e.g., serum creatinine for renal function), and Therapeutic Drug Monitoring (TDM) are essential to refine initial empirical dose calculations.